PRN Archives - Page 9 of 11

Developments

Study finds invasive prostate cancer incidence rising among young men

The incidence of prostate cancer among adolescents and young adults has increased in the U.S. and many other countries during the past three decades, in direct contrast to older men, according to study results published...

November 20, 2019

Markets

Paradigm ups Profound Medical PT to C$45

Paradigm Capital raised its price target for Profound Medical (TSX:PRN; NASDAQ:PROF) to C$45 from C$40 based on the company’s commercialization plan for TULSA-PRO. The stock closed at $12.70 on the TSX on Nov. 5...

November 6, 2019

Markets

Profound Medical to begin trading on NASDAQ

Profound Medical’s (TSX:PRN; OTCQX:PRFMD) common shares have been certified for listing on The Nasdaq Stock Market, with trading slated to begin on Oct. 29 under the stock symbol “PROF.” The company’s common...

October 28, 2019

Developments

Profound Medical implements share consolidation for proposed NASDAQ listing

Profound Medical (TSX:PRN; OTCQX:PRFMF) implemented a one-for-10 consolidation of its shares outstanding to qualify for a potential listing on The NASDAQ Stock Market. Shareholders approved the consolidation at the...

October 11, 2019

Markets

Raymond James starts Profound Medical at OP; PT $4

Raymond James initiated coverage of Profound Medical (TSX:PRN; OTCQX:PRFMF) with an “outperform” rating and price target of $4. The stock closed at 92 cents on Aug. 23. “With its highly experienced management team...

August 26, 2019

Developments

Profound Medical gets FDA clearance to market TULSA-PRO for the treatment of prostate disease

Profound Medical (TSX:PRN; OTCQX:PRFMF) received FDA clearance to market TULSA-PRO for the ablation of prostate tissue, with an FDA label allowing U.S. surgeons to perform procedures on both malignant and benign tissue...

August 16, 2019

Executive Moves

Profound Medical names senior finance executive, Steve Forte, to board

Steve Forte Profound Medical (TSX:PRN; OTCQX:PRFMF) appointed seasoned cross-border finance leader, Steve Forte, as a director and member of the board’s audit committee. Most recently, Mr. Forte was CFO of Clementia...

August 15, 2019

Developments

Profound Medical submits 510(k) application for TULSA-PRO; Reports 292% increase in Q1 revenues

The FDA has accepted Profound Medical’s (TSX:PRN; OTCQX:PRFMF) 510(k) application for premarket clearance of TULSA-PRO, a novel technology that combines real-time MRI, robotically-driven transurethral ultrasound and...

May 6, 2019

Developments

Profound Medical announces first-of-its-kind TULSA-PRO installation

Profound Medical (TSX:PRN; OTCQX:PRFMF) announced the first prostate cancer treatment using a first-of-its-kind TULSA-PRO installation in Trier, Germany. The installation combines Profound’s TULSA-PRO system with...

April 16, 2019

Developments

Profound Medical analyst day illustrates strong case for adoption of TULSA-PRO

Analysts for Paradigm Capital and Canaccord Genuity in new reports said that Profound Medical’s (NASDAQ:PRFMF; TSX:PRN) inaugural analyst day illustrated a strong case for adoption of the company’s TULSA-PRO device for...

April 12, 2019

Tag - PRN

Study finds invasive prostate cancer incidence rising among young men

Paradigm ups Profound Medical PT to C$45

Profound Medical to begin trading on NASDAQ

Profound Medical implements share consolidation for proposed NASDAQ listing

Raymond James starts Profound Medical at OP; PT $4

Profound Medical gets FDA clearance to market TULSA-PRO for the treatment of prostate disease

Profound Medical names senior finance executive, Steve Forte, to board

Profound Medical submits 510(k) application for TULSA-PRO; Reports 292% increase in Q1 revenues

Profound Medical announces first-of-its-kind TULSA-PRO installation

Profound Medical analyst day illustrates strong case for adoption of TULSA-PRO

Subscribe